Dr. Arndt Rolfs, CEO CENTOGENE, presented at JP Morgan Healthcare Conference 2017 about CENTOGENE’s self-amplifying business model – diagnostics, proprietary tools (including the largest, fully curated mutation database for rare diseases – CentoMD®) and pharmaceutical partnerships.
Parkinson’s Institute and Clinical Center partners with CENTOGENE to characterize Parkinson’s patients with targeted gene panel.
Investors and executives are cordially invited to gain insights into the future path of IP-driven biotechnology and genetics. Place: Westin […]
The Accreditation Committee of the College of American Pathologists has renewed accreditation to CENTOGENE AG. Read more in our latest news!
CENTOGENE announces today a new sequencing facility for rare hereditary disorders, which will use Illumina’s HiSeq X® sequencer. With its […]
The “Deutschlandstipendium” is a scholarship that helps support gifted and talented students enrolled at German universities that are public institutions […]
CENTOGENE is proud to contribute to the Face2Gene 60 Day Challenge. This initiative by FDNA was started November 1, 2016. […]
CENTOGENE successfully became part of the Illumina Propel Certification Program for Core and Service Labs. This program acknowledges the generation of highest data quality and application of best practices powered by Illumina.
CENTOGENE GmbH (CENTOGENE) and Interactive Biosoftware (IBS) announce to start their collaboration on the integration of CENTOGENE’s unique genomic database […]
With the upcoming release of CentoMD® 3.1 end of September 2016, CENTOGENE will report genetic information and clinical data from more than 100,000 people worldwide.
With the foundation stone ceremony August 23, 2016, CENTOGENE celebrated the next the construction phase of its new headquarter. Read more!
CentoPortal® enables to keep track of sample progress and manage diagnostic reports, always maintaining the highest data protection and privacy […]
Dr. Volkmar Weckesser is appointed as CENTOGENE’s new CIO as of June 1st, 2016. Dr. Weckesser will help the company transition into new markets and business models based on the further innovation of all IT topics.
With the new release of CentoMD® 3.0, the medical community now has access to an advanced Phenotype-to-Genotype module that enables symptoms-based queries and returns candidate genes as well as associated variants underlying the symptoms of interest.
Summer School Medical Genetics 2016 – From Next-Generation Sequencing to Translational Medicine in Neurological Disease Research With this Summer School, […]
